143 related articles for article (PubMed ID: 29235002)
1. The Added Diagnostic Value of
Addeo P; Poncet G; Goichot B; Leclerc L; Brigand C; Mutter D; Romain B; Namer IJ; Bachellier P; Imperiale A
J Gastrointest Surg; 2018 Apr; 22(4):722-730. PubMed ID: 29235002
[TBL] [Abstract][Full Text] [Related]
2. Limited role of carbidopa-assisted
Imperiale A; Averous G; Helali M; Taieb D; Pessaux P; Goichot B; Addeo P; Bachellier P
Ann Nucl Med; 2019 Sep; 33(9):697-707. PubMed ID: 31214959
[TBL] [Abstract][Full Text] [Related]
3. Small Bowel Carcinoid: The "Dancing Bowel Sign" on 18F-FDOPA PET/CT.
Helali M; Heimburger C; Rohr S; Goichot B; Imperiale A
Clin Nucl Med; 2016 Dec; 41(12):944-945. PubMed ID: 27749424
[TBL] [Abstract][Full Text] [Related]
4. 18F-fluorodihydroxyphenylalanine PET/CT in patients with neuroendocrine tumors of unknown origin: relation to tumor origin and differentiation.
Imperiale A; Rust E; Gabriel S; Detour J; Goichot B; Duclos B; Kurtz JE; Bachellier P; Namer IJ; Taïeb D
J Nucl Med; 2014 Mar; 55(3):367-72. PubMed ID: 24343986
[TBL] [Abstract][Full Text] [Related]
5. PET/CT using ¹⁸F-FDOPA provides improved staging of carcinoid tumor patients in a Canadian setting.
Yakemchuk VN; Jager PL; Chirakal R; Reid R; Major P; Gulenchyn KY
Nucl Med Commun; 2012 Mar; 33(3):322-30. PubMed ID: 22183015
[TBL] [Abstract][Full Text] [Related]
6. Carbidopa-assisted
Helali M; Addeo P; Heimburger C; Detour J; Goichot B; Bachellier P; Namer IJ; Taïeb D; Imperiale A
Ann Nucl Med; 2016 Nov; 30(9):659-668. PubMed ID: 27485404
[TBL] [Abstract][Full Text] [Related]
7. Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET.
Becherer A; Szabó M; Karanikas G; Wunderbaldinger P; Angelberger P; Raderer M; Kurtaran A; Dudczak R; Kletter K
J Nucl Med; 2004 Jul; 45(7):1161-7. PubMed ID: 15235062
[TBL] [Abstract][Full Text] [Related]
8. Intraindividual comparison of
Ouvrard E; Chevalier E; Addeo P; Sahakian N; Detour J; Goichot B; Bachellier P; Karcher G; Taïeb D; Imperiale A
Clin Endocrinol (Oxf); 2021 Jan; 94(1):66-73. PubMed ID: 32790887
[TBL] [Abstract][Full Text] [Related]
9. 18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type.
Balogova S; Talbot JN; Nataf V; Michaud L; Huchet V; Kerrou K; Montravers F
Eur J Nucl Med Mol Imaging; 2013 Jun; 40(6):943-66. PubMed ID: 23417499
[TBL] [Abstract][Full Text] [Related]
10. False-positive findings on 6-[18F]fluor-l-3,4-dihydroxyphenylalanine PET (
Berends AMA; Kerstens MN; Bolt JW; Links TP; Korpershoek E; de Krijger RR; Walenkamp AME; Noordzij W; van Etten B; Kats-Ugurlu G; Brouwers AH; van der Horst-Schrivers ANA
Eur J Endocrinol; 2018 Aug; 179(2):125-133. PubMed ID: 29875288
[TBL] [Abstract][Full Text] [Related]
11. Performances of 18F-FDOPA PET/CT in the Preoperative Evaluation of the Peritoneal Cancer Index in Small Intestine Neuroendocrine Tumors.
Morland D; Jallerat P; Brixi H; Cadiot G; Papathanassiou D; Deguelte S
Clin Nucl Med; 2022 Apr; 47(4):294-298. PubMed ID: 35067541
[TBL] [Abstract][Full Text] [Related]
12. Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors?
Montravers F; Grahek D; Kerrou K; Ruszniewski P; de Beco V; Aide N; Gutman F; Grangé JD; Lotz JP; Talbot JN
J Nucl Med; 2006 Sep; 47(9):1455-62. PubMed ID: 16954553
[TBL] [Abstract][Full Text] [Related]
13. Preoperative
Norlén O; Montan H; Hellman P; Stålberg P; Sundin A
World J Surg; 2018 Feb; 42(2):498-505. PubMed ID: 29159606
[TBL] [Abstract][Full Text] [Related]
14. 18F-FDOPA PET/CT-Guided Radiofrequency Ablation of Liver Metastases from Neuroendocrine Tumours: Technical Note on a Preliminary Experience.
Cazzato RL; Garnon J; Ramamurthy N; Tsoumakidou G; Imperiale A; Namer IJ; Bachellier P; Caudrelier J; Rao P; Koch G; Gangi A
Cardiovasc Intervent Radiol; 2016 Sep; 39(9):1315-21. PubMed ID: 27048487
[TBL] [Abstract][Full Text] [Related]
15. Role of (18) F-FDOPA PET/CT imaging in endocrinology.
Santhanam P; Taïeb D
Clin Endocrinol (Oxf); 2014 Dec; 81(6):789-98. PubMed ID: 25056984
[TBL] [Abstract][Full Text] [Related]
16. High Tumor Uptake on
De Rycke O; Perrier M; Ouvrard É; Mennetrey C; Lachachi C; Bando-Delaunay A; Morland D; Goichot B; Taieb D; Walter T; Cadiot G; Cros J; Hentic O; Ruszniewski P; Lebtahi R; Imperiale A; de Mestier L
J Nucl Med; 2023 Nov; 64(11):1699-1705. PubMed ID: 37652547
[TBL] [Abstract][Full Text] [Related]
17. Small bowel neuroendocrine tumors: A critical analysis of diagnostic work-up and operative approach.
Ethun CG; Postlewait LM; Baptiste GG; McInnis MR; Cardona K; Russell MC; Kooby DA; Staley CA; Maithel SK
J Surg Oncol; 2016 Nov; 114(6):671-676. PubMed ID: 27511436
[TBL] [Abstract][Full Text] [Related]
18. The value of preoperative imaging in small bowel neuroendocrine tumors.
Dahdaleh FS; Lorenzen A; Rajput M; Carr JC; Liao J; Menda Y; O'Dorisio TM; Howe JR
Ann Surg Oncol; 2013 Jun; 20(6):1912-7. PubMed ID: 23283442
[TBL] [Abstract][Full Text] [Related]
19. Clinical utility of functional imaging with ¹⁸F-FDOPA in Von Hippel-Lindau syndrome.
Weisbrod AB; Kitano M; Gesuwan K; Millo C; Herscovitch P; Nilubol N; Linehan WM; Kebebew E
J Clin Endocrinol Metab; 2012 Apr; 97(4):E613-7. PubMed ID: 22259055
[TBL] [Abstract][Full Text] [Related]
20. Functional Imaging in the Follow-Up of Enteropancreatic Neuroendocrine Tumors: Clinical Usefulness and Indications.
Merola E; Pavel ME; Panzuto F; Capurso G; Cicchese N; Rinke A; Gress TM; Iannicelli E; Prosperi D; Pizzichini P; Prasad V; Kump P; Lipp R; Partelli S; Falconi M; Wiedenmann B; Delle Fave G
J Clin Endocrinol Metab; 2017 May; 102(5):1486-1494. PubMed ID: 28324047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
